Key Takeaway: At the EASD 2025 conference, Skye presented findings from a Phase 1b study on nimacimab. The data focused on the safety, tolerability, and pharmacokinetics of the drug in patients with metabolic associated steatotic liver disease (MASLD). The results indicate a positive profile for nimacimab after repeat dosing.
Price reaction · baseline $3.94 (2025-09-18 close) · hit pre-market · 1 other SKYE headline(s) in the window, move may be shared
day 0 close · peak
+1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Nimacimab shows promising safety and tolerability data.
The study contributes valuable insights into MASLD treatment.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
All
Primers
Perspectives
Progress
Press
Nimacimab P1b Safety and Tolerability Data
Date published:
September 19, 2025 9:00 am PDT
Share
Related Documents:
EASD Medical Conference Presentation of P1b Data for Nimacimab
At EASD 2025, Skye presented an assessment of the safety, tolerability, and pharmacokinetics of nimacimab after repeat dosing in subjects with metabolic associated steatotic liver disease (MASLD).
Frequently Asked Questions
What is nimacimab?
Nimacimab is a drug being studied for its effects on metabolic associated steatotic liver disease (MASLD).
What were the findings of the Phase 1b study?
The Phase 1b study assessed the safety, tolerability, and pharmacokinetics of nimacimab after repeat dosing.
Where was the data presented?
The data was presented at the EASD 2025 medical conference.
What is MASLD?
MASLD stands for metabolic associated steatotic liver disease, a condition targeted by nimacimab.